Details

Autor(en) / Beteiligte

• Thomas, Stephen J
• Moreira, Edson D
• Kitchin, Nicholas
• Absalon, Judith
• Gurtman, Alejandra
• Lockhart, Stephen
• Perez, John L
• Pérez Marc, Gonzalo
• Polack, Fernando P
• Zerbini, Cristiano
• Bailey, Ruth
• Swanson, Kena A
• Xu, Xia
• Roychoudhury, Satrajit
• Koury, Kenneth
• Bouguermouh, Salim
• Kalina, Warren V
• Cooper, David
• Frenck, Robert W
• Hammitt, Laura L
• Türeci, Özlem
• Nell, Haylene
• Schaefer, Axel
• Ünal, Serhat
• Yang, Qi
• Liberator, Paul
• Tresnan, Dina B
• Mather, Susan
• Dormitzer, Philip R
• Şahin, Uğur
• Gruber, William C
• Jansen, Kathrin U

Titel

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Ist Teil von

• The New England journal of medicine, 2021-11, Vol.385 (19), p.1761-1773

Ort / Verlag

Boston: Massachusetts Medical Society

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• In a multinational, observer-blinded, randomized trial involving 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age, the efficacy of the BNT162b2 vaccine was 91% against Covid-19 and 97% against severe disease through 6 months of follow-up. In South Africa, where the beta variant was widespread, vaccine efficacy was 100%. Late toxic effects from the vaccine were not observed.